edistride
astrazeneca ab - dapaglifloksiinpropaandioolmonohüdraat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisaks teiste ravimitega ravi 2. tüüpi diabeedi. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
forxiga
astrazeneca ab - dapaglifloksiinpropaandioolmonohüdraat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisaks teiste ravimitega ravi 2. tüüpi diabeedi. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
invokana
janssen-cilag international nv - canagliflozin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5.
vokanamet
janssen-cilag international nv - canagliflozin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vokanamet on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet lisandina toitumise ja treeningu parandamiseks glycaemic hõlma järgmist:patsientidel ei ole piisavalt ohjatud nende maksimaalselt lubatud annustes metformiin alonein patsientidele nende maksimaalselt lubatud annustes metformiin koos teiste glükoosi langetavaid ravimeid, sh insuliini, kui need ei taga piisavat kontrolli glycaemic. patsientidel, juba ravitakse kombinatsioon canagliflozin ja metformiin, nagu eraldi tabletsfor uuringu tulemuste suhtes kombinatsiooni teraapia, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5.
aldara
viatris healthcare limited - imikvimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiootikumid ja kemoterapeutikumid dermatoloogiliseks kasutamiseks - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
veregen salv
nordic pharma s.r.o. - sinekatehhiinid - salv - 100mg 1g 30g 1tk; 100mg 1g 15g 1tk
sedalin gel suukaudne geel
vetoquinol biowet sp. z o.o. - atsepromasiin - suukaudne geel - 35mg 1ml 10ml 1tk
tranquinervin vet süstelahus
le vet. beheer b.v. - atsepromasiin - süstelahus - 10mg 1ml 20ml 1tk; 10mg 1ml 100ml 1tk
promased suukaudne geel
bioveta a.s. - atsepromasiin - suukaudne geel - 35mg 1ml 1ml 1tk; 35mg 1ml 10ml 1tk